10 results about "External beam radiation" patented technology

Radiotherapy is the most widely used and effective anti-tumor therapy, however it can damage healthy tissues surrounding the tumor. One approach to reducing damage to healthy tissue involves irradiation at dose rates far exceeding those currently used in clinical contexts reduces radiation-induced toxicities while maintaining an equivalent tumor response. This is known as the FLASH effect. The mechanism responsible for reduced tissue toxicity following FLASH radiotherapy (FLASH-RT) is still undetermined; multiple hypotheses have been suggested by linking the high dose rate to rapid oxygen depletion, immune response, reduction of peroxyl radical lifetime, preservation of normal tissue stem cells, etc. While effective, proton therapy is underutilized, contributing to fewer than 2% of all external beam radiation treatments. To overcome this shortcoming, provided are methods which utilize the highest energy layer and a universal range shifter (URS) to facilitate rapid spot arc therapy (RAPIDSPARC™).

Systems, devices and methods for internal dose adapted automated external radiation beam therapy, and systems and methods for an automated adaptive workflow to automatically generate a radiation treatment plan based on the internal dose and adapt the treatment plan to a current treatment session using a set of directives.

The present invention provides a WRN inhibitor for use in the treatment of cancer, in particular microsatellite instability-high (MSI- H) or mismatch repair deficient (dMMR) cancer, wherein the treatment further comprises administration of: A. an ionising radiation-based therapy selected from: i) external beam radiation, ii) brachytherapy and Hi) a radiopharmaceutical, or B. carboplatin and paclitaxel; The WRN inhibitor is a compound of formula (1g) or compound C : Formula (C).

Radiotherapy is the most widely used and effective anti-tumor therapy, however it can damage healthy tissues surrounding the tumor. One approach to reducing damage to healthy tissue invoves irradiation at dose rates far exceeding those currently used in clinical contexts reduces radiation-induced toxicities while maintaining an equivalent tumor response. This is known as the FLASH effect. The mechanism responsible for reduced tissue toxicity following FLASH radiotherapy (FLASH-RT) is still undetermined; multiple hypotheses have been suggested by linking the high dose rate to rapid oxygen depletion, immune response, reduction of peroxyl radical lifetime, preservation of normal tissue stem cells, etc. While effective, proton therapy is underutilized, contributing to fewer than 2% of all external beam radiation treatments. To overcome this shortcoming, compact radiotherapy systems are provided that incorporate multi-function components, reducing bot equipment size and expense.

A computerized system (SRS) for radiation therapy support. The system comprises an input interface (IN) for receiving an input image acquired by an imaging apparatus (IA1). The input image represents a region of interest (ROI) internal of a patient (PAT) and acquired before delivery of a dose fraction by a radiation therapy delivery apparatus (RTD). A pre-trained machine learning unit (MLU) of the system is configured to process the input image to detect a medical condition. A communication component (RC) of the system is configured to provide, based on the detected medical condition, an indication for one or more clinical actions to be performed in relation to the patient.

Systems, devices and methods for internal dose adapted automated external radiation beam therapy, and systems and methods for an automated adaptive workflow to automatically generate a radiation treatment plan based on the internal dose and adapt the treatment plan to a current treatment session using a set of directives.

Radiotherapy is the most widely used and effective anti-tumor therapy, however it can damage healthy tissues surrounding the tumor. One approach to reducing damage to healthy tissue involves irradiation at dose rates far exceeding those currently used in clinical contexts reduces radiation-induced toxicities while maintaining an equivalent tumor response. This is known as the FLASH effect. The mechanism responsible for reduced tissue toxicity following FLASH radiotherapy (FLASH-RT) is still undetermined; multiple hypotheses have been suggested by linking the high dose rate to rapid oxygen depletion, immune response, reduction of peroxyl radical lifetime, preservation of normal tissue stem cells, etc. While effective, proton therapy is underutilized, contributing to fewer than 2% of all external beam radiation treatments. To overcome this shortcoming, provided are methods which utilize the highest energy layer and a universal range shifter (URS) to facilitate rapid spot arc therapy (RAPIDSPARC™).

The present invention provides pharmaceutical combinations comprising a WRN inhibitor for the treatment of cancer, wherein the treatment further comprises administration of an ionising radiation-based therapy selected from external beam radiation, brachytherapy and a radiopharmaceutical, or further comprises a combination of carboplatin and paclitaxel.

Systems, devices and methods for augmented reality guidance of imaging systems, external beam radiation systems, and detector plates are described.

Radiotherapy is the most widely used and effective anti-tumor therapy, however it can damage healthy tissues surrounding the tumor. One approach to reducing damage to healthy tissue involves irradiation at dose rates far exceeding those currently used in clinical contexts reduces radiation-induced toxicities while maintaining an equivalent tumor response. This is known as the FLASH effect. The mechanism responsible for reduced tissue toxicity following FLASH radiotherapy (FLASH-RT) is still undetermined, multiple hypotheses have been suggested by linking the high dose rate to rapid oxygen depletion, immune response, reduction of peroxyl radical lifetime, preservation of normal tissue stem cells, etc. While effective, proton therapy is underutilized, contributing to fewer than 2% of all external beam radiation treatments. To overcome this shortcoming, provided are methods which utilize the highest energy layer and a universal range shifter (URS) to facilitate rapid spot arc therapy (RAPIDSPARC™).